Biologic therapies are an efficacious new method of controlling a number of chronic conditions. Data regarding these medications continues to emerge, giving clinicians a greater understanding of their side effects profiles. The biologic agents used in dermatology, particularly the tumor necrosis factor-a inhibitors, have a number of varied dermatologic side effects. In this two-part article, we perform a review of literature regarding cutaneous side effects of infliximab, etanercept, adalimumab, rituximab, efalizumab, and alefacept. In this second part, we discuss injection site reactions, infusion reactions, vasculitis, drug-induced lupus erythematosus, psoriasiform lesions, rebound phenomenon, eczema, atopic dermatitis, and hypersensitivity reactions
alefacept. In this second part, we discuss injection site reactions, infusion reactions, vasculitis, drug-induced lupus erythematosus, psoriasiform lesions, rebound phenomenon, eczema, atopic dermatitis, and hypersensitivity reactions I N THIS SECOND PORTION of our review of the cutaneous side effects of biologic agents, we will explore those reactions that are of an immune nature. While we again group the tumor necrosis factor-a (TNF-a) inhibitors (infliximab, etanercept, and adalimumab) for their tendency toward class effect, infliximab does have a somewhat different profile, likely due to its chimeric murine/human design. This particularly manifests itself in the development of antinuclear antibodies (ANAs).
Using PubMed, we reviewed the literature for publications that reported cutaneous side effects during the use of infliximab, etanercept, adalimumab, rituximab, efalizumab, and alefacept in order to summarize the prevalence of any suspected induced dermatologic conditions associated with these medications. In this article, we discuss injection site reactions, infusion reactions, vasculitis, druginduced lupus erythematosus, psoriasiform lesions, rebound phenomenon, eczema, atopic dermatitis, urticaria, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Infusion Reactions and Injection Site Reactions
An infusion reaction (IR) is defined as any adverse event occurring within a specific window of time around infusion; definitions vary between within 2 hours of infusion, 1 to within 24 hours of infusion. 2 As their only unifying characteristic is time frame, IRs are variable and can consist of pruritus, urticaria, irregularities in blood pressure or heart rate, chills or fevers, and anaphylaxis. In initial clinical trials of 6,443 patients treated for rheumatoid arthritis (RA) and Crohn's disease (CD) with infliximab, rates of IR were 20% (vs 9% for placebo). 1 Further trials have yielded wide-ranging results for rates of IR. In the treatment of RA, rates ranged between 3% (vs 2% for placebo n 5 340) 3 and 21% (no placebo rate available, n 5 213). 4 For CD, rates of acute IR varied between 3.8% (no placebo available, n 5 500) 5 and 24%
(no placebo available, n 5 129). 6 Currently available data regarding pretreatment are inconclusive. Many patients develop antibodies to infliximab, which have been linked to decreased efficacy of the drug 7 as well as to possible increased rates of IRs. 8 Studies looking at pretreatment with corticosteroids to decrease the rate of antibody production and studies looking at pretreatment to decrease the rate of IRs are summarized in Table 1 . Pretreatment tends to increase rates of IR; however, this is likely due to the side effects of the pretreatment drugs themselves. Additionally, likely the single best way to avoid severe IR is with regular treatment. Administration of a second dose of infliximab is strongly associated with a decreased rate of developing antibodies.
Also, the use of episodic infliximab has been associated with 14% of adults developing severe systemic reactions (86 patients treated for CD). 10 Occasional incidents of anaphylaxis have been reported, including one of two patients treated for RA who developed type 1 reactions after not receiving infliximab for approximately 2 years.
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A study by Lequerre and colleagues attempted to establish a management protocol for infliximab-related IRs 12 that is summarized in Table 1 . The publication proposed an extensive algorithm for management of IR; initial management consists of stopping infusion or slowing down to a rate of 60 mL per hour and treating the patient's symptoms as medically appropriate.
Injection site reaction (ISR), often defined as a constellation of symptoms including swelling, erythema, pruritus, and pain around the site of injection, remains the most common cutaneous side effect of the monoclonal antibodies ( Figs 1A and 1B) . The frequency of ISRs in numerous trials can be seen in Table 2 . Of note, the frequency of ISRs appears to vary depending on the disease being treated, the frequency in RA 13 being much higher than in psoriasis (PsO). [14] [15] [16] ISRs from etanercept and adalimumab are reported as decreasing in frequency and intensity as the drug is continued. 13, 17 However, case reports exist of patients whose administration site reactions continue to worsen. 18, 19 Though not often reported, recall reactions (IRs that develop at prior injection sites) may often be associated with administration site reactions. In a study of IRs with etanercept, 8 of the 20 patients who developed IRs developed recall reactions 18 (Fig 2) .
A study of IRs in the use of etanercept found that CD8 + T lymphocytes were the most common cell type in both primary and recurrent IRs and subsequently concluded that this cell type is likely responsible for the delayed hypersensitivity reaction. 18 Typically, IRs can be limited by varying the site of injection. Cutaneous reaction of this variety is very rarely a reason for discontinuation of treatment. Regarding efalizumab, although IRs have been reported, they do not appear to be a significant side effect. Randomized trials have not reported a greater incidence than with placebo. [19] [20] [21] [22] With alefacept, the incidence of IRs has ranged between a rate of 7% of patients treated versus none reported with placebo 23 to 16% of patients treated versus 8% with placebo. 24 
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Cutaneous Vasculitis
Cutaneous vasculitis is not a side effect noted in clinical trials for any of the TNF-a inhibitors, but two noteworthy reports have been published since then, one being a review of Medline catalogued literature, the other being a survey of hospital-based internists and rheumatologists in France. An example of cutaneous vasculitis is depicted in Figure 3 . The basic summaries of these studies are reported in Table 3 .
Since this publication, two noteworthy studies have been done on this topic. The first is a review of literature between 1990 and December 2006 regarding autoimmune diseases associated with TNF-a inhibitor therapy, 25 the results of which are presented in Table 3 . Of note in this study, of patients who continued to use the TNF-a inhibitor, 75% of cases resolved (n 5 12) whereas, when the TNF-a inhibitor was discontinued, 67% had complete resolution (n 5 101). Another significant report is from France, where 1,200 hospital-based rheumatologists and internists were surveyed to report cases of vasculitis with TNF-a inhibitor involvement, 26 the results of which are summarized in Table 3 . Again, in this study, the six patients in which the TNF-a inhibitor was continued experienced a resolution of their symptoms. Of note, TNF-a inhibitors have been used successfully for the treatment of vasculitis. There are reports of its successful use in the treatment of giant cell arteritis 27 and
Churg-Strauss syndrome that was refractory to conventional therapies. 28 However, a trial in which etanercept was used as part of combination therapy in the treatment of Wegener's granulomatosus showed no significant benefit. 29 
Drug-Induced Lupus Erythematosus
The use of TNF-a inhibitors has been linked to the development of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (Fig 4) . This effect was noted during the first clinical trials. Four of 2,292 patients developed SLE with infliximab treatment; in all four cases, the lesions resolved with discontinuation of the drug. 1 Also reported in clinical trials was one case of SLE among 2,334 cases treated with adalimumab. 30 Two recently published review articles summarized the reports of drug-induced SLE form TNF-a inhibitors; the results can be found in Table 4 . Also, we reviewed the published reports of cases of cutaneous lupus not reviewed in the article by Costa and colleagues, [31] [32] [33] [34] [35] [36] [37] [38] the results of which can also be found in Table 4 . Of interest, in the study by Ramos-Casals and colleagues, infliximab was associated with serositis far more than with the other TNFa inhibitors (24% vs 3%, p 5 .008). Cutaneous features were more greatly associated with the use of etanercept (44% vs 12%, p 5 .01). 25 It is noteworthy that the incidence of cutaneous involvement with the diagnosis of SLE associated with TNF-a inhibitors appears to be significantly higher-67% 25 to 73% 39 -than in other causes of drug-induced SLE (9-27% in patients treated with procainamide and hydralazine).
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Although drug-induced SLE related to anti-TNF-a therapy may be an uncommon occurrence, the induction of ANAs is very common. In clinical trials, 11% of those taking etanercept developed ANAs, versus 5% of those on placebo; similar results were found for adalimumab. 17, 30 Initial trials of infliximab found that 62% of treated patients developed ANAs, versus 27% of those on placebo. Prospective trials done since then have confirmed the high rates of ANA development. A study by Louis and colleagues found that 76% of 42 patients being treated with infliximab developed new autoantibodies, including 45% developing ANAs and 33% developing anti-doublestranded deoxyribonucleic acid (dsDNA) antibodies. 41 Another study of infliximab found that, after 24 months, 71 of 125 had developed ANAs. 42 Notably in this study, two patients, both of whom were ANA and dsDNA positive, developed lupus. In this study, ANAs were associated with female gender (p 5 .024) and a 
Psoriasiform Skin Lesions
Infliximab and etanercept have been approved for the treatment of psoriasis and are generally highly efficacious drugs for this condition. It is therefore of the utmost interest that a number of reports of TNF-a-inhibitorinduced psoriasiform lesions have surfaced in postmarketing observations. One large review of 120 cases 43 and 3 smaller reports give some indication as to the rate of induced psoriasiform lesions: the overall rates appear to be between 1.0% and 5.3%. [44] [45] [46] [47] Summaries of these reports are available in Table 5 .
In general, patients are able to tolerate the new-onset psoriasis without discontinuation of the TNF-a inhibitor in favor of the benefit it provides to their primary disease process. [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] The locations of the lesions varied, but there was a strong predilection to develop lesions on the palms and soles, even in the absence of diagnosed palmoplantar pustulosis (PPP) (Fig 5) . Other common sites were the limbs (particularly the pretibial area) and the torso (Fig 6) . Involvement of the scalp and behind the ears was seen, but less so than were other presentations.
The pathophysiology of how TNF-a inhibitors might cause these psoriasiform lesions is not understood. One proposal by de Gannes and colleagues 57 is that there is a cross-regulation between TNF-a and interferon (IFN)-a, which may lead to an increase in IFN, resulting in psoriatic lesions. The investigators looked at the biopsy specimens of 15 patients undergoing TNF-a inhibitor therapy with new onsets or exacerbations of psoriasis and found increased levels of myxovirus-resistance protein A, a surrogate marker for type I IFN activity.
TNF-a-induced psoriatic lesions have also been hypothesized to share a common mechanism to other TNF-a-inhibitor-induced autoreactive processes. As previously stated, these drugs have a well-known side effect of inducing ANA formation and the occasional manifestation of autoimmune syndromes. It is possible that the drugs may induce the activation of autoreactive T cells that in turn lead to psoriatic lesions. 58 Another possibility, which may act independently or complement the prior theory, is that of an up-regulation of chemokine receptors, specifically CXCR3, which increases cutaneous trafficking of autoreactive T cells. Aeberli and colleagues found that treatment of RA patients with infliximab and etanercept resulted in increased numbers of peripheral T cells expressing CXCR3. 59 An alternative mechanism has been proposed for the PPP variant. It has been suggested that the pathogenesis of PPP may be due to a relative impairment of neutrophils induced by the TNF-a inhibitor, which subsequently would allow the growth of Propionibacterium acnes, which is implicated in the pathogenesis of this disease. 60 Another possibility relates specifically to the dysfunction of palmar eccrine sweat glands, related to TNF-a blockade. 61 Figure 3. Leukocytoclastic vasculitis, palpable purpura that developed in a patient with Crohn's disease who was receiving infliximab infusions. This patient developed mild lower-extremity cutaneous leukocytoclastic vasculitis that was not accompanied by systemic symptoms. The purpura resolved after infliximab therapy was discontinued. RA (25) JIA (3) PsA (2) CD (2) AS (1) I (21) 
Rebound Phenomenon in Psoriasis
The most notorious cutaneous effect connected to efalizumab is a rebound phenomenon. This is defined as a relapse of psoriasis that is worse than the original disease (. 125% of the baseline global severity score or psoriasis area-severity index [PASI] score). The results of four clinical trials are reported in Table 6 . Although rebound or changing presentation of psoriasis while on efalizumab has been reported, 62, 63 not all trials reflect this finding.
19,64
Menter and colleagues recently published a study regarding the frequency of rebound with efalizumab and the transitioning of patients to other immunosuppressants. 65 Of their 130 patients who received efalizumab (1 mg/kg per week for 12 weeks), rebound was not observed in those who were PASI-75 responders (n 5 46) but was observed at a significant rate in nonresponders (14 of 49). Rebound was not observed in the 8 patients treated with cyclosporine and was observed in only 2 of 12 patients treated with methotrexate during the transition period. However, breakthrough of psoriatic rebound has been reported even while patients are on cyclosporine. 66 
Eczema
There is evidence that TNF-a inhibitors can lead to eczema (Table 7) ; however, there exists the possibility of significant underreporting with this condition. One study of 142 RA patients found that 47% of the participants had some eczema-like symptoms. 67 
Atopic Dermatitis
The interaction between the TNF-a inhibitors and atopic dermatitis (AD) is a particularly interesting one. There have been a number of case reports of AD as a side effect of TNF-a inhibitors, as well as a proposal for these drugs to be used as a treatment for AD. For published cases, see Table 7 .
Although off-label use of TNF-a inhibitors for AD has found limited appeal, there has been some success in its use. Jacobi and colleagues tested infliximab in the treatment of AD in 9 patients; two of them had maintained an excellent response by 46 weeks after completion of therapy. 68 Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis TNF-a itself is thought to play an important role in the manifesting of erythema multiforme, yet there are cases in which the inhibitors of TNF-a have precipitated it (see Table 7 ). There has been one case report of Stevens-Johnson syndrome associated with rituximab. 69 The patient was a 33-year-old male being treated for non-Hodgkin's follicular lymphoma. During the second infusion of rituximab at 375 mg/m 2 , grade 1 mucositis was noted. The patient received the third infusion on schedule despite weight loss and a pruritic trunk rash. After the diagnosis of StevensJohnson syndrome was made, rituximab was discontinued, and the patient was treated with acyclovir, fluconazole antibiotics, antiseptic cream, and potassium permanganate bath solution. The syndrome persisted for over a year until his death.
The only other cases of note are two cases of toxic epidermal necrolysis (TEN) in two rhesus macaques. 70 There have been no reports of TEN in humans with the administration of rituximab or any of the other biologics we reviewed.
Urticaria
Of the TNF-a inhibitors, infliximab was the only one for which urticaria was reported as a significant side effect. Among RA patients (n 5 688, 6% of those in the treatment group (3-10 mg/kg) developed urticaria as opposed to 1% of those on placebo. In CD patients (n 5 255), 3% of those Urticaria is a common side effect of rituximab; incidence in nonrandomized trials ranged from 3 to 14%. [71] [72] [73] However, two other studies treating B-cell malignancy in 108 patients made no report of any incidents of urticaria. 74, 75 Unfortunately, no double-blind studies indicate rates of urticaria in treatment of malignancy versus rates for placebo. 76 Of interest, the rate of urticaria may be lower when rituximab is used in the treatment of RA. In a placebocontrolled randomized study of 520 patients being treated for RA with two infusions of rituximab (1 g) plus methotrexate, Cohen and colleagues reported urticaria in only 2% of treatment patients for the first infusion and no urticaria for the second. 77 This was not a statistically significant difference from the placebo results.
An unusual pattern of the urticaria associated with rituximab has been observed. One report described a 37-year-old man who developed urticaria 1 hour after an initial infusion at the site of tumor patches and excision scars. 78 The man did not develop any urticaria on later infusions as seems to be a frequent pattern with the use of this drug. A similar reaction was described as occurring in one subject in a study of 10 patients being treated for cutaneous B-cell lymphoma. 79 The authors hypothesized that the reaction in this case was due to the killing of CD20-positive B cells, which led to cytokine release at the site of the tumor, leading to a local urticarial reaction.
Generally, the development of urticaria can be minimized by slowing the infusion rate of rituximab or by pretreating with antihistamines. Pretreatment with antihistamines is in fact so common that the true frequency of urticarial side effects may be underestimated. 78 
Conclusion
Although infusion reactions (IRs) appear to be fairly common with infliximab, trials do not currently indicate usefulness of pretreatment for the prevention of IRs; rather, maintaining a regular dosing schedule appears to be the best way to prevent immunologically mediated complications. Injection site reactions are an issue with etanercept, adalimumab, and alefacept although this can often be managed by varying the site of injection. The relationship between vasculitis and TNF-a inhibitors remains unclear although the two large available studies do not reveal resolution of symptoms with discontinuation of the possibly offending drug, making this relationship suspect. Current literature indicates that both etanercept and the TNF-a inhibitors in general may have an increased rate of cutaneous manifestation of drug-induced lupus when compared with other kinds of drug-induced lupus. The rates of development of new psoriasiform lesions with the TNF-a inhibitors appears to be between 1.0% and 5.3%, although patients are generally able to continue the medication in favor of the treatment it provides for their primary disease process. Urticaria appears to be an issue with infliximab and rituximab alone of the biologics reviewed, and this issue appears to typically be controllable by pretreatment with antihistamines.
